BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 17047077)

  • 1. Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector.
    Kuroda T; Rabkin SD; Martuza RL
    Cancer Res; 2006 Oct; 66(20):10127-35. PubMed ID: 17047077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fusion of the BCL9 HD2 domain to E1A increases the cytopathic effect of an oncolytic adenovirus that targets colon cancer cells.
    Fuerer C; Homicsko K; Lukashev AN; Pittet AL; Iggo RD
    BMC Cancer; 2006 Oct; 6():236. PubMed ID: 17020613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of Icat induces G(2) arrest and cell death in tumor cell mutants for adenomatous polyposis coli, beta-catenin, or Axin.
    Sekiya T; Nakamura T; Kazuki Y; Oshimura M; Kohu K; Tago K; Ohwada S; Akiyama T
    Cancer Res; 2002 Jun; 62(11):3322-6. PubMed ID: 12036951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
    Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
    Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of the transcriptional regulatory sequences of human calponin promoter and their use in targeting a conditionally replicating herpes vector to malignant human soft tissue and bone tumors.
    Yamamura H; Hashio M; Noguchi M; Sugenoya Y; Osakada M; Hirano N; Sasaki Y; Yoden T; Awata N; Araki N; Tatsuta M; Miyatake SI; Takahashi K
    Cancer Res; 2001 May; 61(10):3969-77. PubMed ID: 11358814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tbx3 is a downstream target of the Wnt/beta-catenin pathway and a critical mediator of beta-catenin survival functions in liver cancer.
    Renard CA; Labalette C; Armengol C; Cougot D; Wei Y; Cairo S; Pineau P; Neuveut C; de Reyniès A; Dejean A; Perret C; Buendia MA
    Cancer Res; 2007 Feb; 67(3):901-10. PubMed ID: 17283120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene therapy targeting for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a human alpha-fetoprotein promoter.
    Ido A; Uto H; Moriuchi A; Nagata K; Onaga Y; Onaga M; Hori T; Hirono S; Hayashi K; Tamaoki T; Tsubouchi H
    Cancer Res; 2001 Apr; 61(7):3016-21. PubMed ID: 11306481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel A33 promoter-based conditionally replicative adenovirus suppresses tumor growth and eradicates hepatic metastases in human colon cancer models.
    Cafferata EG; Macció DR; Lopez MV; Viale DL; Carbone C; Mazzolini G; Podhajcer OL
    Clin Cancer Res; 2009 May; 15(9):3037-49. PubMed ID: 19336523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
    Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
    Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
    Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
    Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of gastric cancer cell growth by targeting the beta-catenin/T-cell factor pathway.
    Dvory-Sobol H; Sagiv E; Liberman E; Kazanov D; Arber N
    Cancer; 2007 Jan; 109(2):188-97. PubMed ID: 17149756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of SP5 as a downstream gene of the beta-catenin/Tcf pathway and its enhanced expression in human colon cancer.
    Takahashi M; Nakamura Y; Obama K; Furukawa Y
    Int J Oncol; 2005 Dec; 27(6):1483-7. PubMed ID: 16273202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromosomal instability by beta-catenin/TCF transcription in APC or beta-catenin mutant cells.
    Aoki K; Aoki M; Sugai M; Harada N; Miyoshi H; Tsukamoto T; Mizoshita T; Tatematsu M; Seno H; Chiba T; Oshima M; Hsieh CL; Taketo MM
    Oncogene; 2007 May; 26(24):3511-20. PubMed ID: 17160019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human homolog of NOTUM, overexpressed in hepatocellular carcinoma, is regulated transcriptionally by beta-catenin/TCF.
    Torisu Y; Watanabe A; Nonaka A; Midorikawa Y; Makuuchi M; Shimamura T; Sugimura H; Niida A; Akiyama T; Iwanari H; Kodama T; Zeniya M; Aburatani H
    Cancer Sci; 2008 Jun; 99(6):1139-46. PubMed ID: 18429952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic recombinant herpes simplex virus for treatment of orthotopic liver tumors in nude mice.
    Chung YS; Miyatake S; Miyamoto A; Miyamoto Y; Dohi T; Tanigawa N
    Int J Oncol; 2006 Apr; 28(4):793-8. PubMed ID: 16525626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effects of two newly constructed oncolytic herpes simplex viruses against renal cell carcinoma.
    Fu X; Nakamori M; Tao L; Amato R; Zhang X
    Int J Oncol; 2007 Jun; 30(6):1561-7. PubMed ID: 17487379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The suppression of colon cancer cell growth in nude mice by targeting beta-catenin/TCF pathway.
    Kwong KY; Zou Y; Day CP; Hung MC
    Oncogene; 2002 Nov; 21(54):8340-6. PubMed ID: 12447697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma.
    Wei RC; Cao X; Gui JH; Zhou XM; Zhong D; Yan QL; Huang WD; Qian QJ; Zhao FL; Liu XY
    Hum Gene Ther; 2011 Sep; 22(9):1109-19. PubMed ID: 21361790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-level, beta-catenin/TCF-dependent transgene expression in secondary colorectal cancer tissue.
    Lipinski KS; Djeha AH; Ismail T; Mountain A; Young LS; Wrighton CJ
    Mol Ther; 2001 Oct; 4(4):365-71. PubMed ID: 11592840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene therapy approach in prostate cancer cells using an active Wnt signal.
    Giladi N; Dvory-Sobol H; Sagiv E; Kazanov D; Liberman E; Arber N
    Biomed Pharmacother; 2007 Oct; 61(9):527-30. PubMed ID: 17904788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.